OncoMatch/Clinical Trials/NCT06597734
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Is NCT06597734 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Olutasidenib for chronic myelomonocytic leukemia.
Treatment: Olutasidenib — To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Biomarker criteria
Required: IDH1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylating agent
Exception: treatment-naive arm only; prior HMA not allowed
Participants on the treatment-naive arm must not have received a prior HMA
Lab requirements
Kidney function
calculated creatinine clearance >= 50 mL/min (Cockcroft-Gault, MDRD, or CKD-Epi)
Liver function
Bilirubin <= 2x ULN or <= 3x ULN in participants with Gilbert Syndrome; AST, ALT, and alkaline phosphatase <= 3x ULN
Acceptable liver function: Bilirubin <= 2x ULN or <= 3x ULN in participants with Gilbert Syndrome; AST, ALT, and alkaline phosphatase <= 3x ULN. Acceptable renal function: calculated creatinine clearance >= 50 mL/min (as assessed by Cockcroft-Gault, MDRD, or CKD-Epi validated measures).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify